Tag Archives: Liana Moussatos

Wedbush Remains a Buy on Miragen Therapeutics (MGEN)

In a report released yesterday, Liana Moussatos from Wedbush reiterated a Buy rating on Miragen Therapeutics (MGEN – Research Report), with a price target of $8.00. The company’s shares closed last Monday at $0.64, close to its 52-week low of

Allena Pharmaceuticals (ALNA) Receives a Buy from Wedbush

Wedbush analyst Liana Moussatos reiterated a Buy rating on Allena Pharmaceuticals (ALNA – Research Report) yesterday and set a price target of $26.00. The company’s shares closed last Monday at $1.95, close to its 52-week low of $1.55. According to

Aquestive Therapeutics (AQST) Receives a Buy from Wedbush

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Aquestive Therapeutics (AQST – Research Report), with a price target of $37.00. The company’s shares closed last Monday at $7.24. According to TipRanks.com, Moussatos has currently

Wedbush Sticks to Its Buy Rating for Ascendis Pharma (ASND)

In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a price target of $186.00. The company’s shares closed last Monday at $113.46. According to TipRanks.com, Moussatos is ranked

Omeros (OMER) Receives a Hold from Wedbush

Wedbush analyst Liana Moussatos reiterated a Hold rating on Omeros (OMER – Research Report) today and set a price target of $18.00. The company’s shares closed last Monday at $13.20. According to TipRanks.com, Moussatos has 0 stars on 0-5 star

Wedbush Remains a Buy on Liquidia Technologies (LQDA)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price target of $50.00. The company’s shares closed last Monday at $3.68, close to its 52-week low of $3.25. According to